Kefeng Ding

35PUBLICATIONS
107CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biologyPredictive and prognostic markersPolymers and plastics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|Oct 18, 2026
A lipoprotein-biomimetic nanoplatform for oncogenic KRAS mutation-specific lysosome-targeting protein degradation.

|Aug 31, 2026
First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial.

|Aug 27, 2026
Low SLC8A1 in Colorectal Cancer Dictates Radiotherapy Resistance Through Calcium-Dependent ANXA2+sEVs Driving M2 Polarization of TAMs.

|Jul 24, 2026
Dynamic regulation of lysine and arginine metabolism promotes immune evasion by limiting T cell function in cancer.

|Mar 12, 2026
BEX2 influences the MCL1-Hedgehog signaling axis to regulate the potential of stemness characterization in colorectal cancer.

Yucheng Qian, Jingsun Wei, Yuan Bian

|Feb 18, 2026
Efficacy and safety of tislelizumab as neoadjuvant treatment in patients with stage II-III microsatellite instability-high/mismatch repair-deficient colorectal cancer: a single-arm, multicenter, open-label, prospective, phase II study.

Gong Chen, Yao Ye, Yue Liu

Pageof 6

Frequent Collaborators

8 joint publications

Qian Xiao

5 joint publications

Xue Li

4 joint publications

Ying Yuan

4 joint publications

Yeting Hu